Comparison of Manual and Semi-Automatic [
PSMA-PET/CT
contouring
focal therapy
histopathology
primary prostate cancer
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2020
2020
Historique:
received:
30
08
2020
accepted:
04
11
2020
entrez:
28
12
2020
pubmed:
29
12
2020
medline:
29
12
2020
Statut:
epublish
Résumé
Accurate contouring of intraprostatic gross tumor volume (GTV) is pivotal for successful delivery of focal therapies and for biopsy guidance in patients with primary prostate cancer (PCa). Contouring of GTVs, using 18-Fluor labeled tracer prostate specific membrane antigen positron emission tomography ([ Ten Patients with primary PCa who underwent [ Manual contouring yielded an excellent interobserver agreement with a median DSC of 0.90 (range 0.87-0.94). Volumes derived from scaling SUVmin-max 0-10 showed no statistically significant difference from GTV-Histo and high sensitivities (median 87%, range 84-90%) and specificities (median 96%, range 96-100%). GTVs using semi-automatic segmentation applying a threshold of 20-40% of SUVmax showed no significant difference in absolute volumes to GTV-Histo, GTV-SUV50% was significantly smaller. Best performing semi-automatic contour (GTV-SUV20%) achieved high sensitivity (median 93%) and specificity (median 96%). There was no statistically significant difference to SUVmin-max 0-10. Manual contouring with PET scaling SUVmin-max 0-10 and semi-automatic contouring applying a threshold of 20% of SUVmax achieved high sensitivities and very high specificities and are recommended for [
Identifiants
pubmed: 33365271
doi: 10.3389/fonc.2020.600690
pmc: PMC7750498
doi:
Types de publication
Journal Article
Langues
eng
Pagination
600690Informations de copyright
Copyright © 2020 Spohn, Kramer, Kiefer, Bronsert, Sigle, Schultze-Seemann, Jilg, Sprave, Ceci, Fassbender, Nicolay, Ruf, Grosu and Zamboglou.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. The reviewer TZ declared a past co-authorship with several of the authors WS-S, CJ, and AG to the handling editor.
Références
Lancet. 2020 Apr 11;395(10231):1208-1216
pubmed: 32209449
Theranostics. 2017 Jan 1;7(1):228-237
pubmed: 28042330
J Urol. 2016 Oct;196(4):1261-7
pubmed: 27220897
Int J Radiat Oncol Biol Phys. 2007 Sep 1;69(1):62-9
pubmed: 17707266
Eur J Nucl Med Mol Imaging. 2020 Oct 6;:
pubmed: 33025093
Radiother Oncol. 2015 May;115(2):186-90
pubmed: 25935742
Adv Radiat Oncol. 2019 Sep 27;5(2):212-220
pubmed: 32280821
J Clin Oncol. 2006 May 1;24(13):1990-6
pubmed: 16648499
Prostate Cancer Prostatic Dis. 2018 Jun;21(2):204-211
pubmed: 29858591
Pharmaceuticals (Basel). 2014 Jun 30;7(7):779-96
pubmed: 24983957
Histopathology. 2007 Mar;50(4):472-83
pubmed: 17448023
Theranostics. 2016 Jun 18;6(10):1619-28
pubmed: 27446496
J Nucl Med. 2020 Jan;61(1):51-57
pubmed: 31253741
Radiother Oncol. 2017 Jun;123(3):472-477
pubmed: 28499607
Eur Urol. 2016 Nov;70(5):829-836
pubmed: 26795686
BMC Cancer. 2016 Oct 5;16(1):769
pubmed: 27716184
Eur J Nucl Med Mol Imaging. 2018 Jul;45(7):1170-1178
pubmed: 29468311
Int J Radiat Oncol Biol Phys. 2002 Aug 1;53(5):1097-105
pubmed: 12128107
Radiat Oncol. 2018 Apr 12;13(1):65
pubmed: 29650029
J Nucl Med. 2017 Nov;58(11):1805-1810
pubmed: 28473595
Theranostics. 2019 Apr 13;9(9):2595-2605
pubmed: 31131055
Br J Radiol. 2019 Mar;92(1095):20180948
pubmed: 30676772
J Nucl Med. 2019 Jul;60(7):944-949
pubmed: 30552201
Eur J Nucl Med Mol Imaging. 2020 Nov;47(12):2796-2803
pubmed: 32342192
Sci Rep. 2018 Mar 9;8(1):4254
pubmed: 29523813
Eur J Nucl Med Mol Imaging. 2018 Jun;45(6):1076-1077
pubmed: 29445927
Pharmaceuticals (Basel). 2017 Sep 27;10(4):
pubmed: 28953234
N Engl J Med. 2018 May 10;378(19):1767-1777
pubmed: 29552975
Radiat Oncol. 2013 Jul 22;8:183
pubmed: 23875672
Radiother Oncol. 2018 Apr;127(1):74-80
pubmed: 29336835
Trials. 2011 Dec 05;12:255
pubmed: 22141598
Radiat Oncol. 2018 May 11;13(1):90
pubmed: 29751842
Pathol Oncol Res. 2009 Jun;15(2):167-72
pubmed: 18802790
J Nucl Med. 2020 Apr;61(4):527-532
pubmed: 31562225
Radiother Oncol. 2019 Dec;141:214-219
pubmed: 31431366
J Nucl Med. 2015 May;56(5):668-74
pubmed: 25791990
Eur J Nucl Med Mol Imaging. 2016 Jul;43(8):1400-6
pubmed: 26971788
Lancet Oncol. 2007 Jun;8(6):475-87
pubmed: 17482880